+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

  • ID: 5514498
  • Report
  • November 2021
  • Region: Asia Pacific
  • 82 Pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen, Inc.
  • Apotex, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Toksöz Group

The Asia Pacific Filgrastim Market is expected to witness market growth of 9.4% CAGR during the forecast period (2021-2027).


Factor like the rising population of cancer patients, especially in developing nations like China and India, is expected to unlock bright prospects for the Filgrastim market in the coming years. Although, the high cost attached to these biologics and strict regulatory compliance for the approval of biosimilars in developed nations is expected to hamper the growth of the filgrastim market in the forecast years.


There are several biosimilars research going on across the world, which is expected to accelerate the growth of the market. In addition, the availability of strong pipeline drugs is also estimated to support the growth of the filgrastim market over the forecast period.


One of the major factors augmenting the demand for filgrastim in this region is the increasing cases of cancer in developing nations like India and China. Governments across this region are taking many initiatives to aware people of the early treatment, which is estimated to propel the growth of the regional filgrastim market in the forecast period. However, many people with a low-income level cannot afford treatment for various chronic diseases, especially cancer. This is expected to restrict the demand for filgrastim in the regional market.


Furthermore, as the healthcare system of this region is becoming stronger and governments are introducing better and cheaper healthcare facilities for the people, the demand for filgrastim is expected to increase across this region. Although, the side effects of using filgrastim and the availability of various better alternatives is expected to hinder the growth of the regional filgrastim market during the forecast period.


The China market dominated the Asia Pacific Filgrastim Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $60.3 million by 2027. The Japan market is experiencing a CAGR of 10.4% during (2021 - 2027). Additionally, The India market is expected to witness a CAGR of 10.4% during (2021 - 2027).


Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.



The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group



Scope of the Study

Market Segments Covered in the Report:


By Drug Type


  • Biosimilar and
  • Biologic

By Indication


  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia and
  • Other Indications

By Distribution Channel


  • Hospital Pharmacies
  • Retail Pharmacies and
  • Online Pharmacies

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:


  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksöz Group

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen, Inc.
  • Apotex, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Toksöz Group

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Filgrastim Market, by Drug Type
1.4.2 Asia Pacific Filgrastim Market, by Indication
1.4.3 Asia Pacific Filgrastim Market, by Distribution Channel
1.4.4 Asia Pacific Filgrastim Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Filgrastim Market by Drug Type
3.1 Asia Pacific Biosimilar Market by Country
3.2 Asia Pacific Biologic Market by Country
Chapter 4. Asia Pacific Filgrastim Market by Indication
4.1 Asia Pacific Chemotherapy induced Neutropenia Market by Country
4.2 Asia Pacific Chronic Neutropenia Market by Country
4.3 Asia Pacific Other Indications Market by Country
Chapter 5. Asia Pacific Filgrastim Market by Distribution Channel
5.1 Asia Pacific Hospital Pharmacies Market by Country
5.2 Asia Pacific Retail Pharmacies Market by Country
5.3 Asia Pacific Online Pharmacies Market by Country
Chapter 6. Asia Pacific Filgrastim Market by Country
6.1 China Filgrastim Market
6.1.1 China Filgrastim Market by Drug Type
6.1.2 China Filgrastim Market by Indication
6.1.3 China Filgrastim Market by Distribution Channel
6.2 Japan Filgrastim Market
6.2.1 Japan Filgrastim Market by Drug Type
6.2.2 Japan Filgrastim Market by Indication
6.2.3 Japan Filgrastim Market by Distribution Channel
6.3 India Filgrastim Market
6.3.1 India Filgrastim Market by Drug Type
6.3.2 India Filgrastim Market by Indication
6.3.3 India Filgrastim Market by Distribution Channel
6.4 South Korea Filgrastim Market
6.4.1 South Korea Filgrastim Market by Drug Type
6.4.2 South Korea Filgrastim Market by Indication
6.4.3 South Korea Filgrastim Market by Distribution Channel
6.5 Singapore Filgrastim Market
6.5.1 Singapore Filgrastim Market by Drug Type
6.5.2 Singapore Filgrastim Market by Indication
6.5.3 Singapore Filgrastim Market by Distribution Channel
6.6 Malaysia Filgrastim Market
6.6.1 Malaysia Filgrastim Market by Drug Type
6.6.2 Malaysia Filgrastim Market by Indication
6.6.3 Malaysia Filgrastim Market by Distribution Channel
6.7 Rest of Asia Pacific Filgrastim Market
6.7.1 Rest of Asia Pacific Filgrastim Market by Drug Type
6.7.2 Rest of Asia Pacific Filgrastim Market by Indication
6.7.3 Rest of Asia Pacific Filgrastim Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksöz Group
Note: Product cover images may vary from those shown

Loading
LOADING...